Ultromics

Ultromics is a private, commercial-stage diagnostics company leveraging AI to transform echocardiography analysis. Its core product, the cloud-based EchoGo® platform, hosts FDA-cleared medical devices that assist in the detection of HFpEF and cardiac amyloidosis, addressing significant unmet needs in cardiology. Founded in 2017 as a spin-out from the University of Oxford, the company has established key partnerships with institutions like the Mayo Clinic, secured reimbursement pathways, and processed over 430,000 clinical cases. Ultromics is positioned at the intersection of AI, cardiology, and digital health, with a clear focus on scaling its validated technology across healthcare systems.

EchoGo®: A cloud-based, AI-powered software-as-a-medical-device (SaMD) platform that analyzes routine echocardiogram video clips to detect complex cardiac diseases. It integrates with hospital PACS, uses deep learning algorithms trained on decade-long outcome data, and delivers automated diagnostic reports within 20 minutes.

Ultromics operates in the competitive field of AI for cardiac imaging, facing rivals like Caption Health (acquired by GE HealthCare), Us2.ai, and DiA Imaging Analysis, as well as in-house projects from large ultrasound OEMs (Philips, Siemens, GE). Its differentiation lies in its specific FDA clearances for HFpEF and amyloidosis, strong clinical validation from elite partners, and a secured reimbursement pathway.